Health
New Data from Semaglutide Trials Provides Critical Insights to Guide Next Generation of Therapies Targeting Alzheimer's Pathobiology
Today, Novo Nordisk presented new topline results from their Evoke and Evoke+ phase 3 trials of semaglutide, an oral GLP-1 drug, at the Clinical Trials on Alzheimer's Disease (CTAD) conference. While the trials did not meet their primary endpoints, the presentation highlighted biomarker findings that offer further insight into Alzheimer's pathobiology and underscored a critical shift toward the next era of drug development, which will target the many interrelated biological drivers of this compl
About this update from Novo Nordisk A/s Class B
[{"type":"text","content":"Exploring GLP-1 drugs as preventive therapy may still hold promise within broader strategy targeting Alzheimer's pathways beyond amyloid, ADDF notes","length":152,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Today, Novo Nordisk presented new topline results from their Evoke and Evoke+ phase 3 trials of semaglutide, an oral GLP-1 drug, at the Clinical Trials on Alzheimer's Disease (CTAD) conference. While the trials did not meet their primary endpoints, the presentation highlighted biomarker findings that offer further insight into Alzheimer's pathobiology and underscored a critical shift toward the next era of drug development, which will target the many interrelated biological drivers of this complex disease.","length":559,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/ADDF)","displaySize":"","headline":null,"caption":"(PRNewsfoto/ADDF)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":161,"url":"https://media.zenfs.com/en/prnewswire.com/d15c505f052a2333b1eba36b505a5e6e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x3JF4dHmTjtK1rQlFoPQbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d15c505f052a2333b1eba36b505a5e6e","width":400,"height":161},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/R.4n438t3iKElgBeqML0LQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI1ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d15c505f052a2333b1eba36b505a5e6e","width":400,"height":161}},"href":"https://mma.prnewswire.com/media/588933/ADDF_LOGO_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""While the data presented at CTAD was disappointing, pursuing this type of high-risk, high-reward research into Alzheimer's pathobiology is essential to deepening our understanding of the disease and continuing to advance the science," said Howard Fillit, MD, Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF). "Even negative trials move the field forward as they still teach us something. If we look to the early anti-amyloid studies, which were also negative, they offered critical lessons that informed later trials and ultimately helped bring drugs like Leqembi and Kisunla to market. As we dig further into the data, there i...